RxDoctor Payments Data

Tun Lin, MD

Internal Medicine · Elmhurst, NYNPI 1134195738

Payments from drug & device makers

$18,555in general payments, 2019–2025

Across 949 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • Novo Nordisk$1K
  • Amgen$1K
  • GSK$1K
  • Bayer$1K
  • plus $9K from 38 others

What the payments were for

  • Food & beverage$18,481100%
  • Education$740%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$18,555 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$102,035
Medicare patients
119
Services billed
1,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol313$313,097
VascepaIcosapent Ethyl544$297,753
JardianceEmpagliflozin278$281,077
OzempicSemaglutide213$255,273
LinzessLinaclotide301$251,570
RybelsusSemaglutide122$226,710
KerendiaFinerenone106$116,913
JanuviaSitagliptin Phosphate129$112,990
Trelegy ElliptaFluticasone/Umeclidin/Vilanter128$98,080
BiktarvyBictegrav/Emtricit/Tenofov Ala23$97,220
TrulicityDulaglutide60$94,861
ProliaDenosumab50$83,023
VraylarCariprazine Hcl47$77,025
Breztri AerosphereBudesonide/Glycopyr/Formoterol105$76,124
Janumet XrSitagliptin Phos/Metformin Hcl99$70,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,271$481,983335 claims
AstraZenecaFarxiga, Breztri Aerosphere$3,004$389,222418 claims
AbbVieLinzess, Vraylar, Restasis, Creon, Synthroid$2,162$379,490568 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Jentadueto, Synjardy$737$366,155376 claims
MerckJanuvia, Janumet Xr$726$183,876228 claims
Lilly USA, LLCTrulicity, Mounjaro$846$163,238113 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$1,192$126,500236 claims
BayerKerendia$1,119$116,913106 claims
GileadBiktarvy, Vemlidy$523$113,41035 claims
PfizerAbrysvo, Eliquis$639$91,740216 claims
AmgenProlia$1,261$83,02350 claims
Johnson & JohnsonXarelto$176$65,24645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elmhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →